Mold Testing Decoded: ERMI, HERTSMI-2, and Why Most Tests Lie

The inspector shows up on a Wednesday morning with a pump, two cassettes, and the professional confidence of a man who has run this same test five hundred times. He walks your house. He sniffs at the basement. He runs the pump for eight minutes in the living room, six in the master bedroom. Two weeks later, a report arrives: spore counts within normal limits, no actionable findings, building passes. You are welcome to stop worrying.

You have been sick for eleven months. The fatigue started first, then the brain fog, then the joint pain that your rheumatologist blamed on stress. You feel better when you travel for work and worse every time you come home, and you have started noticing that pattern the way you notice a crack in the ceiling — with the specific dread of someone who already knows what it means but is waiting for permission to say it out loud. The inspector’s report is permission to stop suspecting your house. Your body is running a different report entirely.

This is the mold testing problem in miniature. The standard commercial testing method in the United States was built to protect building owners from liability, not to protect you from exposure. The tool most doctors rely on to rule out mold illness — air sampling — is structurally unable to detect the most dangerous species under the most dangerous conditions. And ERMI mold testing, the DNA-based alternative that EPA researchers validated in 2006 and that actually answers the question you are asking, remains unknown to most inspectors, most doctors, and almost everyone who hasn’t gone down this particular research rabbit hole on their own at 2 a.m.

What follows is a complete guide to what ERMI and HERTSMI-2 actually measure, what the research says about their validity, how to run a correct dual-track investigation, where the most expensive mistakes happen, and what your test numbers mean in clinical terms. If you have been given a clean air sample and told to stop worrying, keep reading.

The Body: What Mold Illness Actually Does to You

Before the test methodology, you need to understand why the right test matters biologically. Mold illness is not the same thing as a mold allergy. An allergy is an IgE-mediated response: your immune system recognizes a foreign protein, makes antibodies, and produces histamine. Standard allergy testing catches this. Antihistamines manage it. It is unpleasant and well-characterized and has nothing to do with what we are discussing here.

The condition that ERMI testing is designed to identify is Chronic Inflammatory Response Syndrome — CIRS — a multi-system inflammatory illness triggered by biotoxins produced by water-damage molds and other organisms. The distinction matters. In CIRS, the problem is not an allergic response to mold protein. It is that certain mold species produce secondary metabolites — trichothecenes from Stachybotrys chartarum, gliotoxins from certain Aspergillus species, sterigmatocystin from Aspergillus versicolor — that are potently immunotoxic, neurotoxic, and cytotoxic. Most people clear these toxins through normal immune pathways and never develop persistent illness from a mold-contaminated building. An estimated 24% of the population, however, carries HLA-DR genetic variants that impair biotoxin clearance. In these individuals, the toxins accumulate rather than clearing, triggering a self-perpetuating inflammatory cascade that standard blood work rarely identifies.

The clinical presentation of CIRS is notoriously diffuse. Fatigue that sleep does not fix. Cognitive impairment — word-finding problems, difficulty concentrating, short-term memory gaps — that neurologists attribute to anxiety. Joint and muscle pain without identifiable structural cause. Unusual sensitivity to light, sound, or chemical smells. Sinus congestion and respiratory symptoms that cycle in and out without resolving. Hormonal disruption. Autonomic dysfunction. The symptom cluster is wide enough that most physicians working through a differential diagnosis land on fibromyalgia, chronic fatigue syndrome, depression, or stress-related illness before they consider the building.

The pattern that should trigger an environmental investigation is temporal: symptoms that improve when you leave the building for extended periods and worsen when you return. A week-long vacation where you feel like yourself again, followed by two days home before the fog returns. Business travel where your energy comes back, and you find yourself dreading the return flight not emotionally but physically. The building correlation is not always clean, because biotoxins have a biological half-life and accumulated load takes time to both clear and rebuild. But if you track your symptoms against your location for thirty days, the pattern usually emerges.

This is the body’s report. Understanding it is why the choice of environmental test is not an academic question. The range of symptoms mold illness produces is broad enough that most physicians miss the diagnosis entirely — and the wrong test is exactly the false reassurance that keeps a susceptible person in a building that is methodically degrading their health.

The Science: Why Air Sampling Lies and ERMI Doesn’t

Air sampling is the default mold test for one primary reason: it is the method that developed when industrial hygiene protocols were written in the 1980s, before polymerase chain reaction technology existed. The methodology involves an air pump drawing a measured volume of air through a collection cassette. Lab technicians examine the cassette under a microscope and count spore shapes. The report lists spores per cubic meter for various morphological categories: Cladosporium, Penicillium/Aspergillus, Stachybotrys, total hyphal fragments.

The fundamental problem is physics. Mold colonies do not produce spores continuously. They pulse — releasing clouds during physical disturbance from foot traffic, HVAC cycling, opening and closing doors, or changes in humidity and temperature. Between pulses, spore counts in the air can be near-zero inside a heavily contaminated building. A five-minute air sample captures what was airborne at that specific moment. It tells you nothing about the other 1,435 minutes of your day, nothing about the previous year of exposure, and nothing about the cumulative burden your body has been absorbing.

The structural bias goes deeper than timing. Stachybotrys chartarum — one of the most clinically important species in mold illness, the one that produces satratoxins and other trichothecenes linked to neurological damage — produces exceptionally heavy spores. They settle rapidly. The species is notorious in the industrial hygiene literature for being absent or barely detectable in air samples even when it is actively colonizing drywall, insulation, and wood framing behind your walls. The test that most inspectors run and most landlords rely on is structurally least capable of detecting the organism you most need to detect.

Morphological identification by microscopy compounds the problem. A trained technician looking at a cassette can distinguish broad categories by shape — round spores versus elongated ones, smooth walls versus rough — but cannot reliably distinguish species within genera. Aspergillus fumigatus and Aspergillus versicolor look similar under a microscope and have profoundly different health implications. The test that cannot tell them apart cannot tell you which one is growing behind your bathroom wall.

ERMI sidesteps these problems by measuring what mold leaves behind rather than what it emits into the air. When mold colonies grow in a building, they shed DNA continuously — fragments of fungal cell walls, spores at various developmental stages, free-floating genetic material from metabolic activity. This material settles into household dust, the accumulated fine-particle layer on floors, in carpet fibers, along baseboards, and inside HVAC filter media. Unlike airborne spores, settled dust is a cumulative archive. It records every mold species that has actively grown in a space over months and years. The heavier and longer the colonization, the denser the genetic signal preserved in the dust.

ERMI exploits this archive through MSQPCR — mold-specific quantitative polymerase chain reaction. PCR amplifies specific DNA sequences with extraordinary sensitivity, allowing detection and quantification of individual species from a small dust sample. Rather than counting shapes under a microscope, MSQPCR identifies specific genetic signatures. It can distinguish Stachybotrys chartarum from Aspergillus versicolor from Chaetomium globosum with a precision that microscopy cannot approach, and it can do this for organisms that are no longer alive and producing spores — because DNA persists long after active growth has stopped.

The ERMI score is a ratio, not a simple count. Group 1 contains 26 water-damage indicator species — organisms that thrive primarily in chronically wet or deteriorating building materials and rarely appear in dry, well-maintained environments. Group 2 contains 10 common environmental species found outdoors and in most buildings regardless of water damage history. The formula:

ERMI = Log10(sum of Group 1 concentrations) − Log10(sum of Group 2 concentrations)

The logarithmic transformation compresses the wide numerical range into an interpretable index. A score near zero means the building’s dust contains roughly equivalent amounts of water-damage indicators and background environmental species — what you would expect in a clean, dry home. Scores above 5 indicate meaningful Group 1 colonization. Scores above 10 indicate severe contamination. The index is calibrated against a national reference population of 1,096 homes from the 2006 HUD American Healthy Homes Survey, so your score has a distributional context: an ERMI of +12 does not just mean elevated, it means you are in the top percentile of contaminated homes nationwide.

HERTSMI-2 is a targeted clinical subset of the full ERMI panel. Where ERMI measures 36 species, HERTSMI-2 measures five: Stachybotrys chartarum, Aspergillus versicolor, Chaetomium globosum, Wallemia sebi, and Penicillium variabile. These five were selected by Dr. Ritchie Shoemaker — the physician who developed the CIRS Biotoxin Illness protocol and did more to define mold illness as a clinical entity than any single researcher — based on their consistent association with the most severe health outcomes in HLA-DR susceptible patients.

HERTSMI-2 uses a weighted point system rather than a ratio formula. Each species receives points based on its concentration per milligram of dust, and the points are summed. Below 11: generally safe for mold illness patients re-entering a building. Between 11 and 15: borderline, requiring clinical judgment based on the individual’s immune status. Above 15: unsafe for anyone in active CIRS treatment. This scoring was derived from clinical outcomes — the thresholds were set because patients who attempted re-entry into buildings scoring above 15 consistently relapsed, regardless of their symptom improvement prior to re-entry.

One critical limitation of HERTSMI-2 that clinicians frequently explain poorly: a low score does not mean a building is mold-free. It means the five most clinically dangerous species for CIRS patients are below threshold. A building can score 6 on HERTSMI-2 and carry a +9 ERMI from species like Aspergillus niger or Cladosporium sphaerospermum that are not in the five-species panel. Use HERTSMI-2 as your clinical re-entry threshold. Use ERMI as your full environmental picture. Using either alone gives you an incomplete answer. The Shoemaker Protocol treats HERTSMI-2 as a minimum screening threshold, not a complete clearance standard.

The Evidence: What the Research Actually Demonstrates

• The Cincinnati Childhood Allergy and Air Pollution Study (Ryan et al., Indoor Air, 2005). Sixty-five homes of asthmatic children and 65 controls, with ERMI compared to standard assessment methods. ERMI scores were significantly higher in the asthmatic children’s homes. Inspector visual assessment — the method that most real estate transactions, rental inspections, and insurance adjustments rely on — failed to discriminate between the groups. Homes that looked clean to a trained inspector had ERMI scores that predicted asthma diagnosis. This study is the direct evidence against the argument that a professional visual inspection combined with air sampling provides adequate clearance for a building. It does not.
• Shoemaker and House (Neurotoxicology and Teratology, 2006): CIRS mechanism. This foundational paper mapped the clinical presentation of mold-triggered multisystem illness and connected it to HLA-DR genotype vulnerability. Patients with certain HLA-DR variants cannot clear biotoxins through normal immune pathways. The trichothecenes from Stachybotrys and gliotoxins from certain Aspergillus species accumulate in these patients and trigger a self-perpetuating inflammatory cascade involving dysregulation of TGF-beta-1, C4a, MMP-9, and MSH. This mechanistic research explains why ERMI’s Group 1 species are clinically more dangerous than Group 2: they are the species producing the biotoxins that specific genotypes cannot clear. The specific mycotoxins involved connect environmental test results to biological impact, and the full clinical database and practitioner certification program are maintained at SurvivingMold.com.
• The spurious-negative air sample problem: EPA’s own data. When EPA researchers compared ERMI scores to concurrent air sampling in the same HUD survey homes, they found that a substantial proportion of homes with ERMI scores above 5 — indicating meaningful water-damage mold presence — had air samples that fell within normal limits. This is the cleanest empirical demonstration of why the two tests are not interchangeable. A clean air sample does not contradict a high ERMI score. They are measuring different variables. One measures what was airborne for five minutes. The other measures what has grown in the building for the past two years. Treating them as equivalent — which every inspector who dismisses ERMI in favor of air sampling is implicitly doing — is a category error with clinical consequences.

The scientific case for ERMI over air sampling is now well-established across independent research groups. Here are the studies that matter, with the methodological detail that explains what they actually prove.

The 2006 HUD American Healthy Homes Survey (Vesper et al., Environmental Science and Technology, 2007). Stephen Vesper and colleagues at the EPA sampled 1,096 homes using the MSQPCR methodology that would become ERMI. This is the foundational paper. It established the national reference distribution, validated that ERMI scores correlated with inspector-assessed water damage and building characteristics known to support fungal growth, and demonstrated that ERMI discriminated between problem homes far more reliably than concurrent spore trap air sampling. Critically, homes with documented water damage history scored significantly and consistently higher than homes without — validating that ERMI was actually detecting the thing it claimed to detect. Without this dataset, the ERMI score would have no reference context. The EPA’s own indoor air quality guidance now acknowledges the limitations of air sampling for characterizing mold reservoirs, a quiet institutional admission that the standard commercial methodology falls short.

The WHEALS Birth Cohort Study (Reponen et al., Journal of Allergy and Clinical Immunology, 2011). Researchers at the University of Cincinnati followed 289 infants from birth to age 7, measuring ERMI in their homes at age one. Children in homes with ERMI scores above 5 were nearly twice as likely to develop asthma by age 7 compared to children in homes scoring below 0. The relationship held after adjustment for allergen sensitization, parental asthma, socioeconomic status, and birth-related confounders. This is one of the most powerful prospective studies connecting a specific mold test to a hard health outcome in children — not self-reported symptoms, not subjective assessment, but physician-diagnosed asthma at age 7. The study used ERMI because ERMI captured cumulative exposure history that mattered for lung development over years. Air sampling, which measures a transient moment, could not have detected this relationship.

One honest limitation worth stating plainly: ERMI was validated as an epidemiological tool for comparing populations of homes, not as a clinical diagnostic instrument with cutoffs derived from randomized controlled trials. The score thresholds used in clinical practice — 0 as average, 5 as elevated, 10 as severe — derive from the national reference distribution rather than from prospective clinical outcome data. This does not make them clinically useless. It means they are probability estimates, not guarantees. An ERMI of +8 means your home sits in the contamination range that epidemiologically predicts elevated health risk. It does not guarantee illness and does not identify the source. A score is one input. Context — biological testing, symptom timeline, HERTSMI-2, genetic susceptibility — is the rest of the case. Large building owners have paid tens of millions in settlements for contamination they concealed, and the testing methodology they used to maintain that concealment was air sampling. The research literature explains exactly why that concealment was so easy to sustain.

The Protocol: How to Run a Complete Mold Investigation

A complete mold investigation runs two parallel tracks simultaneously: environmental and biological. Running only one is the single most common mistake that leads to dismissal, delay, and extended exposure. A high ERMI score combined with consistent biological markers and a characteristic clinical presentation is a case that is very difficult to explain away. Each component in isolation is dismissible. The convergence is not.

This is the framework I call the Dual-Track ERMI Protocol — environmental evidence building in parallel with biological evidence until the combined picture is undeniable.

Environmental Track — Step 1: ERMI Dust Sampling.

Order an ERMI test from either Envirobiomics or MycoMetrics. Envirobiomics was the original EPA contract laboratory for ERMI development and has the longest validated track record. MycoMetrics is the primary laboratory recommended in CIRS clinical circles and runs the combined ERMI/HERTSMI-2 panel. Either laboratory ships a collection kit containing a Swiffer-type cloth or vacuum filter attachment with detailed written instructions. The test costs between $195 and $325 depending on whether you order ERMI alone or the combined panel.

Sample the room where you spend the most time — usually the bedroom, because that is where you accumulate the most sustained exposure hours. If testing a building you are considering moving into, get permission to sample both the primary bedroom and the living room. Do not sample within 24 hours of vacuuming. Do not sample within a week of flooding, major construction, or significant disturbance. You want accumulated fine settled dust, not freshly deposited material from a recent event. The sampling area target is approximately two square feet. Over-sampling dilutes the concentration signal. Under-sampling produces insufficient material for quantification. Follow the lab’s protocol exactly.

Environmental Track — Step 2: HERTSMI-2 as Clinical Threshold.

Order HERTSMI-2 from the same dust sample simultaneously with ERMI. The combined panel from MycoMetrics costs approximately $290 to $325 and requires no additional sample collection. The HERTSMI-2 score gives you the clinical re-entry threshold. Below 11 you can generally proceed with recovery in that environment. Above 15, the building is contraindicated for anyone in active CIRS treatment. Between 11 and 15 requires clinical judgment based on your specific HLA-DR status and current biological markers. The ERMI tells you the full environmental picture. The HERTSMI-2 gives you the five-species clinical threshold. Both together tell you significantly more than either alone.

Environmental Track — Step 3: Source Identification.

A high ERMI tells you the problem exists. It does not tell you where. Source identification requires an industrial hygienist — specifically, one with no financial relationship with a remediation company. Infrared thermal imaging identifies moisture anomalies behind walls and under floors by detecting temperature differentials from evaporative cooling. A calibrated moisture meter confirms what infrared suggests. Tape lift or bulk sampling from suspect materials, sent to the same lab for MSQPCR identification, tells you whether the visual discoloration is mold and which species. Water damage creates active colonization within 24 to 48 hours, so any previous water intrusion event is a legitimate suspect even if it appeared to dry completely. Source identification comes before remediation. Remediation before source identification is a money-spending exercise with a high probability of incomplete resolution.

Biological Track — Step 1: Mycotoxin Urine Testing.

Environmental testing tells you what is in your building. Biological testing tells you what your body has absorbed. The most direct marker for mold toxin accumulation is urinary mycotoxin testing via LC-MS/MS — liquid chromatography-tandem mass spectrometry. RealTime Laboratories and Mosaic Diagnostics (formerly Great Plains Laboratory) are the two established options. Order a panel covering ochratoxin A, aflatoxins, trichothecenes including satratoxins and T-2, and gliotoxin at minimum. The lab methodology and collection protocol are critical — a poorly collected or incorrectly processed urine sample produces false negatives even in heavily exposed patients. The peer-reviewed evidence on urinary mycotoxin detection establishes LC-MS/MS as superior to immunoassay panels for specificity and accurate quantification across a wide concentration range.

Biological Track — Step 2: Visual Contrast Sensitivity Testing.

The VCS test is a ten-minute computerized screen that exploits a specific neurological effect of biotoxin accumulation: impaired contrast detection in the peripheral visual field. Biotoxins crossing the blood-brain barrier damage the thin myelin sheaths around retinal ganglion cells, measurably reducing the visual system’s ability to distinguish subtle contrast gradients. The test is available through SurvivingMold.com for a nominal fee. A positive VCS result in the presence of a high ERMI score is powerfully corroborating — it provides evidence of neurological impact that urine testing and standard blood work routinely miss. Approximately 8% of the population has baseline contrast sensitivity impairment unrelated to biotoxins, which is a source of false positives, but a positive result combined with environmental and urine data significantly strengthens the overall case. The VCS identifies neurological impact before most standard markers show abnormality, making it valuable as an early indicator.

Biological Track — Step 3: Inflammatory Marker Panel.

A CIRS-literate physician should order a panel including TGF-beta-1, C4a, MMP-9, MSH (melanocyte-stimulating hormone), VEGF, and HLA-DR genotyping. These markers form the mechanistic picture of whether your immune system is actively dysregulated in the specific pattern consistent with biotoxin illness. Elevated TGF-beta-1 and C4a with suppressed MSH in the presence of a high ERMI score and a building-correlated symptom timeline is a clinical presentation that requires a formal CIRS diagnosis and the structured sequential treatment the Shoemaker Protocol provides. HLA-DR genotyping identifies whether you carry one of the susceptibility variants — approximately 24% do — which contextualizes your threshold and your treatment timeline. The full recovery roadmap integrates these biomarkers with environmental remediation in the specific sequenced protocol that clinical outcomes support.

Biological Track — Step 4: Supporting Clearance.

While results are pending and you are working with a physician on formal treatment, understand that your body is actively trying to clear what it has accumulated. The three primary clearance pathways for mycotoxins are biliary excretion via the gut, sweat, and breath. Supporting all three simultaneously — through binders, infrared sauna, and breathing work — accelerates biological clearance that clinical treatment eventually formalizes. This is not a substitute for leaving the contaminated building. It is what you do while executing the environmental strategy in parallel.

Sequencing principle: If you are still in the suspect building, run environmental testing first. There is no value in extensive biological panels until you have environmental data to correlate them against. If you are already out of the building, run both tracks simultaneously. Do not return to the contaminated building to test it while you are in active treatment. Post-remediation clearance testing should happen before you re-enter, not after.

A second ERMI costs $200. A relapse costs months.

The Mistakes: What Extends Your Exposure by Years

The testing and remediation landscape contains traps that are partly structural — built into the industry’s financial incentives — and partly psychological — built into how people process information they do not want to act on. Knowing them in advance is the difference between a six-month resolution and a five-year nightmare.

• Mistake 1: Trusting a clean air sample when your body says otherwise. This is the most common and most costly mistake. An inspector runs air sampling, the cassettes come back within normal limits, and you are told the building passes. You have been sick for eleven months. You feel better when you travel and worse when you return. The report says nothing is wrong. Here is the thing about that report: it measured what was airborne for six minutes. Stachybotrys chartarum, which is producing satratoxins in your wall cavity, was not shedding spores at 10:23 Tuesday morning when the pump ran. The report is not lying. It is just answering a different question than the one you needed answered. Run the ERMI yourself if the inspector will not order it. The Dual-Track ERMI Protocol starts with environmental evidence, and the environmental evidence you need is in the dust, not the air. The range of ways mold illness presents is wide enough that a clean air sample provides genuine false reassurance to genuinely sick people every day.
• Mistake 2: Allowing the building owner to manage your testing. The entity that owns your building has financial and legal interests that are directly opposed to yours when mold contamination is the issue. They benefit from tests that come back clean. They select the inspector, frame the scope of testing, and receive the reports first. A landlord-commissioned air sample that comes back negative carries exactly zero evidentiary weight against an ERMI you ordered, paid for, and received directly from the laboratory. Your rights as a tenant are legally meaningful, but only if you have independent test results in your own possession. Order your own ERMI. Provide a copy of the results to your landlord in writing with return receipt. Document the timeline. Your independent DNA-based evidence of contamination and their inspector’s clean air sample are not equal arguments. One is a PCR quantification of accumulated genetic material. The other is five minutes of air pump. A court will understand the difference.
• Mistake 3: Remediating without source identification, then remediating again. A remediator removes the visibly affected drywall, sprays a fungicide, installs new material, and hands you a certificate of completion. You move back in. Three months later, symptoms return. The reason is almost always one of two things: the source was not fully identified and additional hidden colonization was left in place, or the remediation process itself aerosolized spores that redistributed into new areas of the home. Post-remediation ERMI — collected 30 days or more after remediation completion, with the HVAC system running normally — is the only way to verify that the dust record has actually been cleared. Without it, you have a remediator’s certificate. With it, you have DNA evidence of what remains. The remediation industry has its own mythology about what actually eliminates mold colonization, and clearance testing is the mechanism that holds remediators to an objective standard rather than their own professional judgment.
• Mistake 4: Using a moderate ERMI score to justify staying. An ERMI of +4 is easier to rationalize than an ERMI of +12. Not that bad. Middle of the road. Could be worse. If you do not have mold illness, that assessment might be correct. If you are HLA-DR susceptible, if your HERTSMI-2 shows elevated Aspergillus versicolor, and if your TGF-beta-1 and C4a are already elevated, a score of +4 may be sufficient to prevent recovery. The ERMI is an environmental probability estimate calibrated against a population. Your biological response to that environment depends on your specific immune genetics, your cumulative exposure history, your total antigenic load, and what other stressors your system is managing simultaneously. A number that looks moderate in a population context can be individually intolerable. Reducing ongoing load with air purification and humidity control can help at the margins, but it does not change the genetic record in your dust or the source that is adding to it.
• Mistake 5: Testing once and treating the result as permanent. Buildings are dynamic systems. A slow pipe fitting failure, a condensate drain that blocks for two months, a roof repair that introduces moisture into an unconditioned attic space — any of these can restart a colonization cycle in a building that tested clean eighteen months ago. HVAC systems are a particular vulnerability, because they distribute spores and particulate throughout an entire building and can sustain contamination long after a visible source has been physically removed. If you have a documented history of mold illness, annual ERMI testing in your primary residence is reasonable practice. If symptoms you have not experienced in months begin returning without other obvious explanation, repeat ERMI before assuming the problem is internal or unrelated to your environment. The test is not expensive. Delayed diagnosis is.
• Mistake 6: Knowing the protocol and not using it. I will say this plainly because it applies to every health topic and most people will recognize it immediately: reading a correct protocol for running a mold investigation, understanding each step, agreeing with the logic, and then continuing to live in the building while your cognitive function declines is a specific failure mode that deserves its own name. Call it protocol paralysis. The barrier is usually not information — you now have the information — it is the disruption cost of acting on it. Moving is expensive and difficult. Confronting a landlord is uncomfortable. Spending $300 on a test that might confirm a conclusion you have already suspected is frightening in its own way. The alternative is an eleven-month average diagnosis delay, which is where most CIRS patients find themselves after following the conventional medical pathway. The Dual-Track ERMI Protocol is available to you today. The dust sample requires twenty minutes of effort. The biological markers require a blood draw and a urine collection. The information asymmetry that currently exists between building owners and occupants narrows the moment you run the test.

FAQ: ERMI, HERTSMI-2, and Mold Testing

Editorial StandardsCorrectionsMedical DisclaimerAbout Our ContentAffiliate DisclosureSite Map